Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to baseline and participant meets Hanifin and Rajka criteria.~* Eczema area and severity index (EASI) score ≥ 16;validated Investigator´s Global Assessment for AD (vIGA-AD) score ≥ 3 and ≥ 10% Body Surface Area Involvement of Atopic Dermatitis (BSA of AD) involvement at the Baseline Visit.~* Baseline weekly average of daily Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4.~* Documented history of inadequate response to previous systemic treatment defined as documented history of previous inadequate response to at least one prior systemic treatment for AD OR for whom other systemic treatments are otherwise medically inadvisable.~Exclusion Criteria:~* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.~* History of an organ transplant which requires continued immunosuppression.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Upadacitinib (Type: EXPERIMENTAL): Participants will receive upadacitinib dose A daily in period 1. Eligible participants will receive upadacitinib dose B daily in period 2.
- Dupilumab followed by Upadacitinib (Type: EXPERIMENTAL): Participants will receive dupilumab as per its label in period 1. Eligible participants will receive upadacitinib dose A in period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).